トルブタミドおよび他のスルフォニル尿酸によるカテキオラミンの放出抑制
Science (New York, N.Y.)
|March 21, 1975
まとめ
トルブタミドとスルフォニル尿素は,腎上腺と心臓からカタチョラミン放出を抑制する. このシンパト・アドレナ系阻害は,血糖を低下させる効果に寄与する可能性があります.
科学分野:
- 薬理学 薬理学とは
- エンドクリノロジー エンドクリノロジー
- 神経科学は神経科学である.
背景:
- サルフォニル尿素は,2型糖尿病の管理に一般的に使用されます.
- 低血糖効果の背後にある正確なメカニズムは,完全に解明されていません.
- シンパト・アドレナ系は,グルコース・ホメオスタシスに役割を果たします.
研究 の 目的:
- カテコアミン放出に対するスルフォニル尿素の効果を調査する.
- シンパソアドレナ系抑制と硫黄素尿素の低血糖作用の間の潜在的な関連性を調査する.
主な方法:
- 浸潤された猫の腎上腺からカテキオラミンの放出を研究した.
- ニコチン刺激を受けた後の,孤立した豚の心臓から[3-H]ノルエピネフリンの放出を調べた.
- 異なるスルフォニル尿素の抑制効力を比較した.
主要な成果:
- トルブタミドおよび他のスルフォニル尿素は,自発的およびニコチン誘発のカタチョラミン放出を著しく抑制しました.
- ニコチンによって誘発される[3-H]ノルエピネフリンの放出は,また,スルフォニル尿素によって抑制された.
- カテコロアミン放出を抑制するスルフォニル尿素の効能は,その低血糖活性と相関していた.
結論:
- スルフォニル尿素は,交響性腎上腺系からカテキオラミンの放出を阻害する.
- シンパソアドレナ系を阻害することは,スルフォニル尿素の低血糖作用に寄与する要因である可能性があります.
さらに関連する動画
関連する概念動画
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...